MSF launches patent opposition database to aid pharmaceutical protestors

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

MSF launches patent opposition database to aid pharmaceutical protestors

Health activists who want to challenge patents given to drugs companies have been given a new tool to make the process easier

Médecins Sans Frontières has today launched a database enabling activists to share information and experiences about opposing patents using one central portal.

The unveiling of the Patent Opposition Database comes 10 years after a landmark decision by Thailand's Central Intellectual Property and International Trade Court to overturn the patent on then-key HIV drug didanosine, after a patent opposition was filed by AIDS Access Foundation and three Thai people living with HIV.

The database contains a searchable listing of 45 patent oppositions relating to key medicines and more than 200 other supporting documents that will aid in the building of future patent oppositions.

In particular it provides a simple guide to legislation covering patent opposition and the processes involved in challenging a patent at the pre-grant or post-grant stage.

It also links to copies of opposition documents that have been filed in countries including Brazil, India and Thailand and calls for users to submit prior art documents that activists in other parts of the world can use for their own opposition applications.

“It’s a myth that every patent application that is filed is valid,” said Michelle Childs, Director of Policy Advocacy for MSF’s Access Campaign. “When you look closely, a patent application may fail one or more of the legal tests it needs to pass. The idea behind this database is to help civil society and patient groups stop unwarranted patents from blocking people’s access to more affordable medicines.”

MSF pointed to a number of cases in which patient groups have already challenged pharmaceutical patents. In India, for example, groups successfully challenged a patent application for the HIV fixed-dose-combination zidovudine/lamivudine on the grounds that it was not a new invention, but simply the combination of two existing drugs.

After that, the Cancer Patient Aid Association filed a pre-grant opposition to an application made by Novartis, which was seeking patent protection for the salt form of imatinib, the active ingredient in its cancer-treating drug Glivec. India’s Supreme Court is now considering whether the country’s patent office was right to refuse to grant Novartis a patent.

more from across site and SHARED ros bottom lb

More from across our site

The firm has taken the bold step of ditching the billable hour as its default pricing mechanism – watch now as rivals follow suit
The IP services provider is targeting further expansion as cost and efficiency pressures push law firms and in-house teams to rethink how they manage global portfolios
Two experienced UPC practitioners join the UK IP boutique’s growing German operation, with further recruitment planned as the firm expands in Europe
The Australian IP firm is taking on bigger rivals in Southeast Asia, betting that agility and transparent pricing can help it stand out
The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
Gift this article